Streetbeat News

ELV

Elevance Health Inc.

https://www.elevancehealth.com

Industry

Medical - Healthcare Plans

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Open

387.02

Mkt cap

89B

Volume

1.7M

High

389.87

P/E Ratio

14.03

52-wk high

567.26

Low

383.83

Div yield

0.02

52-wk low

362.21

Elevance Health's fourth-quarter earnings are expected to benefit from growing premiums, though higher expenses may offset these gains.

Portfolio Pulse from

January 20, 2025 | 3:45 pm

The article discusses the Q4 outlook for Elevance Health (ELV), focusing on Wall Street's estimates for key metrics to assess the company's potential performance for the quarter ending December 2024.

Portfolio Pulse from

January 17, 2025 | 3:30 pm

Elevance Health is considered a strong buy despite a 30% stock decline, due to its solid fundamentals and market position. It benefits from trends like an aging population, but faces risks from rising healthcare costs and a shrinking Medicaid member base.

Portfolio Pulse from

December 26, 2024 | 8:15 am

Elevance Health's stock has dropped by 29.6% in Q4 as the company reallocates resources to more profitable areas and makes strategic acquisitions.

Portfolio Pulse from

December 20, 2024 | 9:15 pm

Robbins LLP is investigating Elevance Health Inc. (NASDAQ: ELV) for potential breaches of fiduciary duties by its officers and directors. The investigation aims to determine if securities laws were violated, impacting shareholders.

Portfolio Pulse from

December 12, 2024 | 4:00 am

Elevance Health has demonstrated strong financial performance with a 9.1% revenue CAGR and 13.7% EPS growth over the past decade. Despite recent share price weakness, its long-term fundamentals remain strong, presenting an investment opportunity. The stock is attractively valued with a forward PE of 11.2x, lower than its 10-year average, and potential upside from AI integration.

Portfolio Pulse from

December 11, 2024 | 4:00 pm

Elevance Health's stock fell after its subsidiary, Anthem Blue Cross Blue Shield, faced backlash over a new anesthesia policy. The company has since reversed the policy change.

Portfolio Pulse from

December 06, 2024 | 6:00 pm

Johnson Fistel, LLP is investigating Elevance Health, Inc. for potential securities law violations related to misrepresentation or failure to disclose material information, which may have led to investor losses.

Portfolio Pulse from

December 04, 2024 | 6:30 pm

Elevance Health (ELV) has seen a 20% decline in its stock price over the past three months due to challenges like higher benefit costs, increased debt, and member attrition in its Medicaid business. These issues are causing investor concerns.

Portfolio Pulse from

November 12, 2024 | 7:15 pm

Johnson Fistel, LLP is investigating Elevance Health, Inc. for potential securities law violations related to misrepresentation or failure to disclose adverse information, which may have led to investor losses.

Portfolio Pulse from

November 07, 2024 | 10:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.